Jeffrey L. Lennox

TL;DR: In HIV-infected patients with limited treatment options, raltegravir plus optimization background therapy provided better viral suppression than optimized background therapy alone for at least 48 weeks.

TL;DR: This research presents a meta-analysis of the immune system’s response to Epstein-Barr virus, which has the potential to improve the quality of life of patients and reduce the likelihood of adverse events.

TL;DR: Raltegravir is a well tolerated alternative to efavirenz as part of a combination regimen against HIV-1 in treatment-naive patients and has rapid and potent antiretroviral activity, which was non-inferior to that of efvirenz at week 48.

TL;DR: When combined with an optimized background regimen in both studies, a consistently favorable treatment effect of raltegravir over placebo was shown in clinically relevant subgroups of patients, including those with baseline characteristics that typically predict a poor response to antiretroviral therapy: a high HIV-1 RNA level, low CD4 cell count, and low genotypic or phenotypic sensitivity score.

TL;DR: IDSA considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances.